Lucid Diagnostics price target lowered to $3 from $3.80 at Cantor Fitzgerald

Cantor Fitzgerald analyst Charles Duncan lowered the firm’s price target on Lucid Diagnostics to $3 from $3.80 and keeps an Overweight rating on the shares. The firm views Lucid’s EsoGuard/EsoCheck offerings favorably in light of their potential to become the new first-line screen for Barrett’s esophagus-esophageal adenocarcinoma in the conservatively estimated $25B U.S. market, and views the company’s stock as materially undervalued, the analyst tells investors in a research note.